ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO335

Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial

Session Information

Category: Genetic Diseases of the Kidneys

  • 1102 Genetic Diseases of the Kidneys: Non-Cystic


  • Frishberg, Yaacov, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel
  • Michael, Mini, Texas Children's Hospital, Houston, Texas, United States
  • Groothoff, Jaap, Emma's Children's Hospital, Amsterdam, Netherlands
  • Shasha-Lavsky, Hadas, Galilee Medical Center, Nahariya, North, Israel
  • Lieske, John C., Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States
  • Simkova, Eva, Al Jalila Children's Specialty Hospital, Dubai, Dubai, United Arab Emirates
  • Sellier-Leclerc, Anne-Laure All, Hopital Femme Mere Enfant, Bron, Auvergne-Rhône-Alpes , France
  • Devresse, Arnaud, Cliniques universitaires Saint-Luc, Bruxelles, Belgium
  • Guebre Egziabher, Fitsum, Edouard Herriot Hospital, Lyon, France
  • Bakkaloglu, Sevcan A., Gazi Universitesi, Ankara, Ankara, Turkey
  • Mourani, Chebl, Hotel-Dieu De France, Beirut, Lebanon
  • Saqan, Rola, Jordan University of Science and Technology, Irbid, Jordan
  • Singer, Richard F., Canberra Health Services, Garran, Australian Capital Territory, Australia
  • Willey, Richard G., Alnylam Pharmaceuticals Inc, Cambridge, Massachusetts, United States
  • Gansner, John M., Alnylam Pharmaceuticals Inc, Cambridge, Massachusetts, United States
  • Magen, Daniella, Rambam Health Care Campus, Haifa, Haifa, Israel

Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by hepatic oxalate overproduction leading to progressive kidney disease. In PH1, plasma oxalate (POx) increases as kidney function declines; in CKD 3b–5, POx is typically elevated and is associated with an increased risk of systemic oxalosis, making it a relevant trial endpoint. In the ILLUMINATE-C 6-month (M) primary analysis, administration of lumasiran, an RNA interference therapeutic designed to reduce hepatic oxalate production, produced substantial POx reductions and acceptable safety in PH1 patients with impaired kidney function. Here we present 12M results.


ILLUMINATE-C (NCT04152200) is an ongoing Phase 3, single-arm study (Cohort A: N=6, no hemodialysis [HD] at study start; Cohort B: N=15, on HD). The primary analysis period is followed by an extension period (EP) of up to 54M. Key inclusion criteria included genetically confirmed PH1, eGFR ≤45 mL/min/1.73m2, and POx ≥20 μmol/L.


All 21 patients entered the EP (median [range] exposure, 14.2 [8.3-19.7] M). As of the M12 assessments, 2 Cohort A patients (baseline eGFR, 8.6-16.0 mL/min/1.73m2) initiated HD. In Cohort B, 1 patient received a kidney transplant, discontinued HD, and continued lumasiran; 1 received a liver/kidney transplant and discontinued lumasiran. POx mean % reduction from baseline at M12 was 69.3% and 34.3% in Cohorts A and B, respectively; mean absolute reduction was 60.7 and 42.4 µmol/L. POx AUC0-24h mean % reduction from baseline between HD sessions was 40.9% at M12 (Cohort B). Most burdensome symptoms improved or remained stable with lumasiran. The most common lumasiran-related adverse events (AEs) were mild, transient injection-site reactions. There were no deaths or lumasiran-related serious or severe AEs, discontinuations, or withdrawals.


Lumasiran showed sustained POx reductions in PH1 patients with CKD 3b–5, with an acceptable safety profile through M12. The impact on systemic oxalosis and transplant outcomes will be further monitored in the EP.


  • Commercial Support –